UBS Initiates Coverage On Chimera Investment With Neutral Rating, Announces Price Target of $5.5
BenzingaDec 6, 2023 07:52 ET
Chimera Investment Analyst Ratings
BenzingaDec 6, 2023 07:49 ET
Credit Suisse Maintains Neutral on Chimera Investment, Lowers Price Target to $5.5
BenzingaMay 19, 2023 07:42 ET
What 5 Analyst Ratings Have To Say About Chimera Investment
BenzingaMay 17, 2023 14:01 ET
RBC Capital Maintains Outperform on Chimera Investment, Lowers Price Target to $6
BenzingaMay 17, 2023 08:26 ET
RBC Cuts Price Target on Chimera Investment to $6 From $7, Maintains Outperform Rating
MT NewswiresMay 17, 2023 07:55 ET
Keefe, Bruyette & Woods Maintains Market Perform on Chimera Investment, Lowers Price Target to $5.5
BenzingaMay 9, 2023 09:55 ET
Keefe, Bruyette & Woods Adjusts Price Target on Chimera Investment to $6.25 From $7, Maintains Market Perform Rating
MT NewswiresApr 24, 2023 10:35 ET
Keefe, Bruyette & Woods Maintains Market Perform on Chimera Investment, Lowers Price Target to $6.25
BenzingaApr 24, 2023 07:51 ET
Credit Suisse Sticks to Their Hold Rating for Chimera Investment (CIM)
TipRanksMar 9, 2023 11:30 ET
Credit Suisse Reiterates Neutral on Chimera Investment, Maintains $6.5 Price Target
BenzingaMar 9, 2023 08:10 ET
RBC Capital Reiterates Outperform on Chimera Investment, Maintains $7 Price Target
BenzingaMar 7, 2023 08:03 ET
RBC Cuts Price Target on Chimera Investment to $7 From $11, Noting Unexpected Dividend Cut, Maintains Outperform Rating
MT NewswiresOct 5, 2022 08:12 ET
Chimera Investment Analyst Ratings
Benzinga Analyst RatingsOct 5, 2022 07:28 ET
RBC Capital Maintains Outperform on Chimera Investment, Lowers Price Target to $7
Benzinga Real-time NewsOct 5, 2022 07:28 ET
Barclays Adjusts Price Target on Chimera Investment to $9 From $11, Reiterates Underweight Rating
MT NewswiresJul 18, 2022 07:28 ET
Chimera Investment Price Target Cut to $9.00/Share From $11.00 by Barclays
Dow JonesJul 18, 2022 07:18 ET
Chimera Investment Is Maintained at Underweight by Barclays
Dow JonesJul 18, 2022 07:18 ET
Chimera Investment analyst ratings
Benzinga Analyst RatingsJul 18, 2022 07:08 ET
Barclays Maintains Underweight on Chimera Investment, Lowers Price Target to $9
Benzinga Real-time NewsJul 18, 2022 07:08 ET
No Data
No Data